Evidence Hub

Dose Pattern Evolution and Therapeutic Benefit in Patients on Solifenacin or Fesoterodine Treatment in Daily Clinical Practice

J. M. García-Mediero, F. Sánchez-Ballester, D. Arumí, I. Lizarraga

2016

828 participants

Abstract

Aim: To explore in daily clinical practice

the evolution in time of the fesoterodine and solifenacin dose pattern and

assess the therapeutic benefit provided by the highest dose of these anti-muscarinics.

Patients and Methods: This was a post-hoc analysis of data from an

observational, cross-sectional, retrospective and multicenter study. Adult

patients diagnosed with over active bladder (OAB) who initiated fesoterodine or

solifenacin treatment were included. Data on the prescribed treatment and dose,

change of dose, reasons for switching and treatment benefit were recorded.

Results: A total of 828 subjects were analyzed (262 receiving solifenacin and

566 fesoterodine). Most subjects were women with a mean time since diagnosis of

more than one year and aged around 60 years old. The majority of patients

initiated the OAB treatment with the lowest available dose (64% fesoterodine

vs. 77% solifenacin). At the follow-up visit 54% of the fesoterodine group and

66% of the solifenacin opted for dose escalation. At the study visit, 70.1%

fesoterodine vs. 43.3% solifenacin remained on the highest dose. A

significantly greater proportion of subjects receiving fesoterodine 8 mg,

reported higher improvement in terms of both patient-reported-treatment benefit

and clinical global impression compared with solifenacin 10 mg (p < 0.05).

Conclusion: In routine clinical practice more than half of the patients opted

for the higher dose and remained on it over time, suggesting a desire for…

How strong is the evidence?

Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 828 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free